These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 31527206)

  • 21. Recurrent, isolated factor X deficiency in myeloma: repeated normalization of factor X levels after cytostatic chemotherapy followed by late treatment failure associated with the development of systemic amyloidosis.
    Schwarzinger I; Stain-Kos M; Bettelheim P; Pabinger I; Kyrle P; Kalhs P; Kapiotis S; Jäger U; Lechner K
    Thromb Haemost; 1992 Dec; 68(6):648-51. PubMed ID: 1287879
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [A case of retroperitoneal hemorrhage due to multiple myeloma complicated with factor X deficiency and amyloidosis].
    Tsukazaki K; Sukuwa M; Muratani Y; Shimada S; Mine M; Kuratsune H; Tomonaga M
    Nihon Naika Gakkai Zasshi; 1991 May; 80(5):757-8. PubMed ID: 1875111
    [No Abstract]   [Full Text] [Related]  

  • 23. Treatment of amyloidosis associated factor X deficiency.
    Spero JA; Lewis JH; Hasiba U; Ellis LD
    Thromb Haemost; 1976 Apr; 35(2):377-81. PubMed ID: 989637
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A novel combination of bortezomib, lenalidomide, and clarithromycin produced stringent complete response in refractory multiple myeloma complicated with diabetes mellitus - clinical significance and possible mechanisms: a case report.
    Takemori N; Imai G; Hoshino K; Ooi A; Kojima M
    J Med Case Rep; 2018 Feb; 12(1):40. PubMed ID: 29454372
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma.
    Salwender H; Bertsch U; Weisel K; Duerig J; Kunz C; Benner A; Blau IW; Raab MS; Hillengass J; Hose D; Huhn S; Hundemer M; Andrulis M; Jauch A; Seidel-Glaetzer A; Lindemann HW; Hensel M; Fronhoffs S; Martens U; Hansen T; Wattad M; Graeven U; Munder M; Fenk R; Haenel M; Scheid C; Goldschmidt H
    BMC Cancer; 2019 May; 19(1):504. PubMed ID: 31138244
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials.
    Chhabra S; Callander N; Watts NL; Costa LJ; Thapa B; Kaufman JL; Laubach J; Sborov DW; Reeves B; Rodriguez C; Chari A; Silbermann R; Anderson LD; Bal S; Dhakal B; Nathwani N; Shah N; Medvedova E; Bumma N; Holstein SA; Costello C; Jakubowiak A; Wildes TM; Schmidt T; Orlowski RZ; Shain KH; Cowan AJ; Dholaria B; Cornell RF; Jerkins JH; Pei H; Cortoos A; Patel S; Lin TS; Usmani SZ; Richardson PG; Voorhees PM
    Transplant Cell Ther; 2023 Mar; 29(3):174.e1-174.e10. PubMed ID: 36494017
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Acquired hemophilia A and plasma cell neoplasms: a case report and review of the literature.
    Jalowiec KA; Andres M; Taleghani BM; Musa A; Dickenmann M; Angelillo-Scherrer A; Rovó A; Kremer Hovinga JA
    J Med Case Rep; 2020 Oct; 14(1):206. PubMed ID: 33121522
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment Patterns and Clinical and Economic Outcomes in Patients With Newly Diagnosed Multiple Myeloma Treated With Lenalidomide- and/or Bortezomib-containing Regimens Without Stem Cell Transplant in a Real-world Setting.
    Chari A; Parikh K; Ni Q; Abouzaid S
    Clin Lymphoma Myeloma Leuk; 2019 Oct; 19(10):645-655. PubMed ID: 31377207
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma.
    Hobeika L; Self SE; Velez JC
    BMC Nephrol; 2014 Sep; 15():156. PubMed ID: 25267524
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gastric invasion of multiple myeloma presenting as gastrointestinal bleeding.
    Nakajima K; Sueki Y; Koshiishi M; Kawashima I; Nozaki Y; Mitsumori T; Kirito K
    Int J Hematol; 2015 Jun; 101(6):525-6. PubMed ID: 25916464
    [No Abstract]   [Full Text] [Related]  

  • 31. Acquired factor V deficiency in a patient with myeloma and amyloidosis.
    Quek JKS; Wong WH; Tan CW; Tha MH; Nagarajan C; Lee LH; Ng HJ
    Thromb Res; 2018 Apr; 164():1-3. PubMed ID: 29427868
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bone formation following lenalidomide-dexamethasone combination therapy in cases of multiple myeloma refractory to high-dose chemotherapy with bortezomib and autologous peripheral blood stem cell transplantation: report of a case and review of the literature.
    Sekiguchi Y; Ichikawa K; Wakabayashi M; Sugimoto K; Tomita S; Izumi H; Nakamura N; Sawada T; Ohta Y; Komatsu N; Noguchi M
    Int J Clin Exp Pathol; 2015; 8(8):9609-19. PubMed ID: 26464727
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Outcomes of Maintenance Therapy with Bortezomib after Autologous Stem Cell Transplantation for Patients with Multiple Myeloma.
    Sivaraj D; Green MM; Li Z; Sung AD; Sarantopoulos S; Kang Y; Long GD; Horwitz ME; Lopez RD; Sullivan KM; Rizzieri DA; Chao NJ; Gasparetto C
    Biol Blood Marrow Transplant; 2017 Feb; 23(2):262-268. PubMed ID: 27856369
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bleeding due to acquired dysfibrinogenemia as the initial presentation of multiple myeloma.
    Siddiq N; Bergstrom C; Anderson LD; Nagalla S
    BMJ Case Rep; 2019 Jul; 12(7):. PubMed ID: 31320370
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acquired Isolated Factor VII Deficiency in Plasma Cell Dyscrasias: A Brief Presentation of Two Plasma-Cell-Leukemia-Related Cases and Review of Literature.
    Furlan A; Sartori F; Gherlinzoni F
    J Clin Med; 2023 Sep; 12(18):. PubMed ID: 37762778
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Rare Cause of Acquired Factor X Deficiency in an 87-Year-Old Female.
    Bangolo A; Waykole T; Niazi B; Sajja C; Akhter M; Gupta B; Elias S
    Case Rep Hematol; 2021; 2021():1138329. PubMed ID: 34840836
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma.
    Baertsch MA; Mai EK; Hielscher T; Bertsch U; Salwender HJ; Munder M; Fuhrmann S; Dührsen U; Brossart P; Neben K; Schlenzka J; Kunz C; Raab MS; Hillengaß J; Jauch A; Seckinger A; Hose D; Luntz S; Sonneveld P; Lokhorst H; Martin H; Goerner M; Hoffmann M; Lindemann HW; Bernhard H; Blau IW; Scheid C; Besemer B; Weisel KC; Hänel M; Dürig J; Goldschmidt H;
    Blood Cancer J; 2021 Jan; 11(1):1. PubMed ID: 33414374
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [First-line treatment of multiple myeloma].
    Breitkreutz I; Raab M; Goldschmidt H
    Internist (Berl); 2019 Jan; 60(1):23-33. PubMed ID: 30552458
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Plasma cells with hairy projections and Auer rod-like inclusions in a patient with multiple myeloma.
    Sharma P; Sachdeva MUS; Ahluwalia J; Malhotra P
    BMJ Case Rep; 2017 Aug; 2017():. PubMed ID: 28775092
    [No Abstract]   [Full Text] [Related]  

  • 40. [Improvement of hepatomegaly after treatment with autologous hematopoietic stem cell transplantation followed by bortezomib and dexamethasone in Bence-Jones protein κ-type of multiple myeloma with systemic amyloidosis].
    Nagamachi Y; Yamauchi N; Muramatsu H; Miyajima N; Inomata H; Okamoto T; Nozawa E; Gotoh Y; Koyama R; Ihara K; Nishisato T; Kato J
    Rinsho Ketsueki; 2015 Mar; 56(3):323-8. PubMed ID: 25876787
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.